Skip to content

Feng Yang

Department of Neurology, Jining First People's Hospital, Jining, Shandong, China.

2 papers in the library · 115 citations · publishing 2006-2025

Papers

Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.

The Journal of pharmacology and experimental therapeutics August 1, 2006 Michael A Ansonoff, Jiwen Zhang, Traci Czyzyk et al. 101 citations

Salvinorin A, the active component of the hallucinogenic plant Salvia divinorum, produces pain relief (antinociception) and lowers body temperature in mice by activating the kappa-opioid receptor. These effects were observed after injection of salvinorin A or a similar compound, salvinorinyl-2-propionate, into the brain of normal mice, but not in mice genetically lacking the kappa-opioid receptor. Salvinorin A showed high affinity specifically for the kappa-1 subclass of opioid receptors. In contrast, salvinorin B, an inactive derivative, had no effect on pain or body temperature. The findings confirm that salvinorin A acts through the kappa-opioid receptor to produce its behavioral effects.

Neurotoxicity mechanisms and clinical implications of six common recreational drugs.

Frontiers in pharmacology January 1, 2025 Jing Wang, Yulei Hao, Di Ma et al. 14 citations

Recreational abuse of six addictive drugs—methamphetamine, cocaine, synthetic cathinones, ketamine, nitrous oxide, and heroin—damages the nervous system through shared toxic pathways, including oxidative stress, mitochondrial dysfunction, excitotoxicity, and neuroinflammation. Psychostimulants disrupt monoaminergic signaling, causing cognitive impairment and neurovascular damage. Dissociative anesthetics impair glutamatergic transmission and mitochondrial function, worsening excitotoxicity and neuronal death. Opioids target the brain's reward system, inducing oxidative stress and neuroinflammation. Current treatments focus on symptom management and behavioral therapy; emerging options like antioxidants and NMDA receptor modulators need further validation.